Anyone know why AMRN has not pursued hemodialysis patients? Pure EPA resulted in a more than 80% decrease in heart attacks for this population in a 2 year Japanese study. That population by itself represents a huge divergence in sales from current paltry numbers. Just wondering? The FDA probably thinks that's outside the flat earth arguments they spew.
Just want to provide a public service announcement to all the new bulls here. The FDA pulled an obscene act at the Advisory Committee and by subsequently nullifying the SPA. They stopped the safest drug available for high triglyceride sufferers that is the ONLY drug available that does not raise LDL-C on statins. Vascepa also has properties for reducing inflammation that the FDA completely ignored. The FDA will likely say no again on January 15th regardless of what you have read. I love me some Vascepa, but those criminals running this gov't agency are only interested in large pharma concerns it seems. Best of luck. Just a note of caution from someone who lost everything. Hedge your bets.